Neutropenia associated with the comedication of quetiapine and valproate in 2 elderly patients

Journal of Clinical Psychopharmacology

Volumn 32, Issue 3, 2012, Pages 416-417

  Hung, Wei Chih ^a   Hsieh, Ming H ^b  

^a Bali Psychiatric Center   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

LITHIUM CARBONATE; OLANZAPINE; QUETIAPINE; VALPROIC ACID;

ADULT; AGED; AUDITORY HALLUCINATION; BIPOLAR DISORDER; CASE REPORT; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IRRITABILITY; LETTER; LEUKOCYTE COUNT; LITHIUM BLOOD LEVEL; MALE; MONOTHERAPY; NEUTROPENIA; NEUTROPHIL COUNT; PRESCRIPTION; PRIORITY JOURNAL;

AGED, 80 AND OVER; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BIPOLAR DISORDER; DEMENTIA, VASCULAR; DIBENZOTHIAZEPINES; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HALLUCINATIONS; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; PSYCHOMOTOR AGITATION; TREATMENT OUTCOME; VALPROIC ACID;

EID: 84861082548     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182549d2d     Document Type: Letter

References (12)

1. Clark N, Weissberg E, Noel J. Quetiapine and leukopenia. Am J Psychiatry. 2001;158:817-818.
2. Croarkin P, Rayner T. Acute neutropenia in a patient treated with quetiapine. Psychosomatics. 2001;42:368.
3. Ruhe HG, Becker HE, Jessurun P, et al. Agranulocytosis and granulocytopenia associated with quetiapine. Acta Psychiatr Scand. 2001;104:311-314.
4. Shankar BR. Quetiapine-induced leucopenia and thrombocytopenia. Psychosomatics. 2007;48:530-531.
5. Cowan C, Oakely O. Leukopenia and neutropenia induced by quetiapine. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:292-294.
6. Rahman A, Mica LM, Fischer C, et al. Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. Ann Pharmacother. 2009;43:822-830.
7. Raggi MA, Mandrioli R, Sabbioni C, et al. Atypical antipsyhotics: Pharmacokinetics, therapeutic drug monitoring and pharmacological interaction. Curr Med Chem. 2004;11:279-296.
8. Kasper S, Brecher M, Fitton L, et al. Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. Int Clin Psychopharmacol. 2004;19:281-289.
9. Krupp P, Barnes P. Clozapine-associated agranulocytosis: Risk and aetiology. Br J Psychiatry. 1992;160:38-40.
10. Oluboka O, Haslam D, Lam T, et al. Quetiapine-induced leucopenia: Possible dosage-related phenomenon. Can J Psychiatry. 2003;48:65-66.
11. Aichhorn W, Marksteiner J, Walch T, et al. Influence of age, gender, body weight and valproate comedication of quetiapine plasma concentrations. Int Clin Psychopharmacol. 2006;21:81-85.
12. Wen X, Wang JS, Kivistö KT, et al. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: Preferential inhibition of cytochrome P450 2C9 (CYP 2C9). Br J Clin Pharmacol. 2001;52:547-553.